Overcoming the Straw Man Effect in Oncology: Visualization and Ranking of Chemotherapy Regimens Using an Information Theoretic Approach.

45 Notably, the only triplet compared with Pom-Dex, pomalidomide-cyclophosphamide-dexamethasone, was in a randomized phase II trial with a weak surrogate primary end point (overall response rate) and borderline significance ( P = .035). 46 Given that Pom-Dex is relatively well tolerated, 47 , 48 and that toxicities are a serious concern for modern myeloma drugs, 49 our findings may have real-world significance.

also in 7,017 other papers